Shihao Zheng1,2
Chengyuan Xue1,2
Size Li1,2Xiaobin Zao1,3Xiaoke Li1,4Qiyao Liu1,2Xu Cao1,4Wei Wang1,2Wenying Qi1,2Hongbo Du1,4Peng Zhang5*Yongan Ye1,4*- 1Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
- 2Beijing University of Chinese Medicine, Beijing, China
- 3Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
- 4Liver Diseases Academy of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
- 5Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China
Liver cirrhosis arises from liver fibrosis and necroinflammation caused by various mechanisms of hepatic injury. It is a prevalent condition in clinical practice characterized by hepatocellular dysfunction, portal hypertension, and associated complications. Despite its common occurrence, the etiology and pathogenesis of liver cirrhosis remain incompletely understood, posing a significant health threat. Effective prevention of its onset and progression is paramount in medical research. Symptoms often include discomfort in the liver area, while complications such as sarcopenia, hepatic encephalopathy, ascites, upper gastrointestinal bleeding, and infection can arise. While the efficacy of Western medicine in treating liver cirrhosis is uncertain, Chinese medicine offers distinct advantages. This review explores advancements in liver cirrhosis treatment encompassing non-pharmacological and pharmacological modalities. Chinese medicine interventions, including Chinese medicine decoctions, Chinese patent medicines, and acupuncture, exhibit notable efficacy in cirrhosis reversal and offer improved prognoses. Nowadays, the combination of Chinese and Western medicine in the treatment of liver cirrhosis also has considerable advantages, which is worthy of further research and clinical promotion. Standardized treatment protocols based on these findings hold significant clinical implications.
Epidemiology of liver cirrhosis
Liver cirrhosis is the result of fibrosis and necrotizing inflammation stemming from various mechanisms of liver injury (Figure 1). Histologically, the condition is characterized by the presence of regenerated nodules encased in dense fibrous septa, leading to the disappearance of parenchyma and subsequent collapse of liver structure (Schuppan and Afdhal, 2008; Ginès et al., 2021). This process ultimately results in the distortion and deformation of the liver’s vascular architecture. The term “cirrhosis” originates from the Greek word “kirrhos,” denoting a yellow or yellowish-brown hue, in reference to the coloration of nodules visible on the liver’s surface.Today, liver cirrhosis represents the advanced pathological progression of chronic liver disease, characterized by persistent inflammation, restructuring of hepatic lobes, and the development of pseudolobules and nodules (Nie et al., 2023). And Liver cirrhosis it can present clinically in two main stages: an asymptomatic stage known as compensated cirrhosis, and a symptomatic stage known as decompensated cirrhosis. In the latter stage, the primary manifestations, including jaundice, ascites, gastrointestinal bleeding, and encephalopathy, pose significant risks to human health (Costa et al., 2022).
Figure 1. Liver cirrhosis and its associated factors. Mainly includes the causes of morbidity and complications of liver cirrhosis, as well as modern medical and Chinese medicine treatments for liver cirrhosis. TCM: Traditional Chinese Medicine.
Liver cirrhosis, a significant component of digestive diseases, presents a substantial economic burden in numerous countries. However, the scarcity of data regarding the incidence and mortality rates of liver cirrhosis in regions with high prevalence, notably Africa, has garnered considerable attention from scholars globally. The prevalence of liver cirrhosis is estimated to be between 4.5% and 9.5% of the global population (Starr and Raines, 2011; Llovet et al., 2016; Fateen and Ryder, 2017). Annually, approximately two million deaths worldwide are attributed to liver diseases, with one million resulting from cirrhosis and another one million due to viral hepatitis and hepatocellular carcinoma (HCC) (GBD, 2017 Cirrhosis Collaborators, 2020). Liver cirrhosis is the 11th most common cause of death globally and the third leading cause of death among individuals aged 45–64 years. When combined with liver malignancies, cirrhosis accounts for 3.5% of all deaths worldwide (Asrani et al., 2019). A major study found that approximately 2.2 million adults in the U.S. have cirrhosis, and that the annual death rate from cirrhosis rose from 14.9 per 100,000 to 21.9 per 100,000 in the decade to 2021, placing a serious healthcare burden on U.S. society, as well as a significant economic impact globally (Tapper and Parikh, 2023; Wazir et al., 2023). Surprisingly, deaths due to cirrhosis already accounted for 2.4% of global deaths in 2019, and the number of people dying from cirrhosis is expected to continue to increase over the next decade (Huang et al., 2023). However, it is important to note that data on mortality rates related to chronic liver diseases, such as cirrhosis, may be conservative, and research studies may not fully capture the true extent of the global burden (Asrani et al., 2013). The treatment of liver diseases such as liver cirrhosis is an onerous and arduous task, waiting for further exploration.
Understanding liver cirrhosis in modern medicine
Etiology and pathogenesis of liver cirrhosis
The causes of cirrhosis are diverse, with most chronic liver diseases potentially leading to liver fibrosis and eventual cirrhosis. Common causes include alcoholic liver disease, non-alcoholic fatty liver disease, hepatitis C, and hepatitis B. In most Asian countries, chronic hepatitis B infection predominates as the main cause of cirrhosis, while in European and American nations, hepatitis C, alcoholic, or non-alcoholic fatty liver diseases are primary contributors. Viral hepatitis, specifically hepatitis B and hepatitis C, often underlie liver fibrosis or cirrhosis, while hepatitis A and hepatitis E typically manifest as acute self-limiting hepatitis. Chronic hepatitis E is rare and mainly occurs in individuals with immune deficiencies or those using immunosuppressive drugs, akin to non-hepatotropic hepatitis mechanisms such as Epstein-Barr virus (Liu et al., 2024) and cytomegalovirus (Heusel et al., 2024). Some scholars have proposed autoimmune mechanisms, chronic liver diseases, schistosomiasis, and malnutrition as potential cirrhosis causes, yet these remain contentious and necessitate further investigation (Bartolotta et al., 2022). However, from the perspective of Chinese medicine, various pathogenic factors can lead to the emergence of pathological factors such as qi stagnation, dampness-heat, blood stasis, etc., which injure the liver and ultimately lead to the onset and development of cirrhosis.
Liver cirrhosis represents a post-injury liver repair response wherein hepatic stellate cell (HSC) activation plays a pivotal role, alongside liver sinusoidal endothelial cells (LSECs) regulation, cytokine release, and fibrous scar tissue deposition (Kisseleva and Brenner, 2021). Cirrhosis typically progresses from chronic hepatitis to liver fibrosis and ultimately cirrhosis (Romanelli and Stasi, 2016) (Figure 2). Following liver injury from various pathological factors, macrophages, T cells, and other inflammatory cells secrete numerous chemokines and inflammatory factors, instigating immune cell recruitment to the injury site. This cascade activates the liver’s inflammatory response, causing hepatocyte inflammation, damage, and potentially necrosis and apoptosis (Campana and Iredale, 2017; Krenkel et al., 2018; Engelmann et al., 2023). Within this inflammatory milieu, HSCs transition into myofibroblasts, prompting excessive extracellular matrix (ECM) production, and angiogenic factor release (Hernandez-Gea and Friedman, 2011; Roehlen et al., 2020). Research suggests that HSCs typically constitute 5%–8% of a healthy human liver, primarily regulating ECM synthesis and degradation to modulate hepatic sinusoidal blood supply (El-Serag, 2012).
Figure 2. Mechanisms of liver cirrhosis. Under the stimulation of the relevant etiological factors, the quiescent hepatic stellate cells are activated, and some of them proliferate and differentiate, eventually forming ECM deposits, leading to the development of liver fibrosis and then cirrhosis, while some other cells are restored to healthy hepatocytes by external interventions or their own causes, etc.
LSECs (Gracia-Sancho et al., 2021; McConnell et al., 2023) serve as vital immune barriers within the liver, safeguarding against foreign body recognition, phagocytosis, and degradation. However, under inflammatory conditions, LSECs lose their specialized phenotype, leading to pore loss. Damaged LSECs secrete pro-inflammatory and pro-fibrotic factors, activating HSCs and promoting ECM deposition between hepatic sinusoidal spaces. This process forms fibrous septa with vascular proliferation, culminating in hepatic fibrosis progression. Continued fibrosis leads to septal extension, pseudolobule formation, and eventual liver parenchyma destruction and vascular structure distortion, resulting in cirrhosis (Ni et al., 2017; Li, 2022; Gao et al., 2024). Autophagy, a mechanism involved in liver injury, influences disease development (Kouroumalis et al., 2021). Early-stage autophagy protects LSECs, maintaining endothelial cell phenotype and liver cell redox balance to prevent oxidative stress. Loss of endothelial autophagy exacerbates endothelial dysfunction, impacting liver fibrosis by specifically regulating HSC activation.
A healthy liver performs various functions, including metabolism, detoxification, nutrient storage, and bile production for digestion (Mancak et al., 2024). Triggers such as hepatic fat accumulation, drug-induced injury, excessive alcohol consumption, or viral hepatitis can induce liver inflammation and fibrosis. Advanced fibrosis and substantial liver structure damage lead to cirrhosis, eventually predisposing individuals to liver cancer (Toh et al., 2023). Regular medical check-ups are advisable, especially for individuals with chronic liver diseases, family history, or other risk factors, as early detection and treatment are crucial in combating end-stage liver disease (Yang et al., 2019).
Liver cirrhosis and its complications
Liver cirrhosis and sarcopenia
Sarcopenia represents a prevalent complication in individuals with liver disease, with mounting evidence indicating its significant prognostic implications for cirrhosis patients. Ponziani and Gasbarrini (2018) reported that sarcopenia afflicts approximately 70% of individuals with end-stage liver disease. Compared to numerous chronic conditions, sarcopenia’s occurrence in cirrhosis patients is notably high. While its prevalence in patients with cardiovascular diseases stands at 29.7%, those with liver cirrhosis experience a strikingly elevated rate of 48.1% (Kim et al., 2017). Research by Ponziani and Gasbarrini (2018) found sarcopenia incidence among cirrhosis patients to fluctuate between 20% and 70%. Additionally, a study by Hanai et al. (2016) observed cirrhosis patients exhibiting over twice the muscle loss rate compared to healthy individuals, with a notable increase in mortality when muscle loss exceeded 3%. Presently, burgeoning research delves into cirrhosis and sarcopenia, with findings indicating potential pathogenic links to systemic inflammatory responses (Keller et al., 2011; Sinclair et al., 2016), heightened catabolic states (Plauth et al., 2019), liver-muscle interactions (Qiu et al., 2013; Welch et al., 2020), inadequate energy intake (Cheung et al., 2012), and disruptions in protein homeostasis (Periyalwar and Dasarathy, 2012; Tandon et al., 2021).
Liver cirrhosis and hepatic encephalopathy
Hepatic encephalopathy stands as a prevalent complication of cirrhosis and ranks among the primary causes of mortality in affected patients. It manifests as a metabolic disorder stemming from central nervous system dysfunction in individuals with acute or chronic liver ailments. Nevertheless, its occurrence in cirrhosis patients signifies heightened mortality risk and a relatively grim prognosis (Shen et al., 2015). Presently, the precise pathogenesis of hepatic encephalopathy remains incompletely elucidated, with theories encompassing ammonia toxicity, neurotransmitter imbalances, and amino acid perturbations, among which ammonia toxicity serves as a focal point. Risk factors for hepatic encephalopathy in cirrhosis patients encompass infections, ascites, electrolyte imbalances, and upper gastrointestinal bleeding. Furthermore, Maqsood et al. (2006) identified prothrombin time as a prominent precipitating factor for hepatic encephalopathy. Additionally, hyponatremia-induced reduction in extracellular osmotic pressure and resultant cerebral edema are deemed significant contributors to hepatic encephalopathy development, with a reported 8% increase in hepatic encephalopathy risk for every 1 mmol/L reduction in serum sodium (Iwasa and Takei, 2015; Bossen et al., 2019). Addressing the substantial incidence of hepatic encephalopathy in cirrhosis patients warrants profound attention and contemplation for future interventions.
Liver cirrhosis and ascites
Ascites represent a prevalent complication of cirrhosis and stand as a common ailment encountered in clinical practice (Ginés et al., 1987; Runyon et al., 1992). Its emergence often signals an advanced stage of cirrhosis, with a prognosis characterized by complexity and variability. Particularly in refractory cirrhosis, ascites often accompany other cirrhosis-related complications, leading to a poor clinical outlook and a significant decline in patients’ quality of life. Cirrhotic ascites refers to the accumulation of free fluid within the abdominal cavity of cirrhosis patients. Substantial ascitic fluid can induce symptoms like reduced appetite and abdominal distension, profoundly impacting patients’ quality of life and heightening the risk of complications such as hepatic encephalopathy, hepatorenal syndrome, and spontaneous peritonitis (Tandon and Garcia-Tsao, 2008). The 1-year mortality rate among cirrhosis patients with ascites reaches 15%, while the 5-year mortality rate can soar as high as 44% (Biecker, 2011). The mechanism underlying ascite formation involves various factors, including portal hypertension, hypoalbuminemia, inadequate effective circulating blood volume, and heightened production of hepatic lymph fluid, all contributing to ascite development.
Liver cirrhosis and upper gastrointestinal bleeding
Liver cirrhosis is often accompanied by multiple system involvement, and complications such as upper gastrointestinal bleeding and secondary infection often occur in the late stage. Upper gastrointestinal bleeding is the most common fatal complication, and the overall mortality rate of upper gastrointestinal bleeding can reach 30 percent (de Franchis and Baveno VI Faculty, 2015; Dango et al., 2017). The risk of portal hypertension and upper gastrointestinal bleeding can be determined by detecting the pressure gradient of hepatic veins. It is worth noting that this examination is a traumatic examination, so electronic endoscopy, a non-traumatic examination, is often used clinically to evaluate the degree of esophageal varices in patients with cirrhosis, so as to prevent the occurrence of upper gastrointestinal bleeding (Song and Kim, 2019). Related studies have confirmed that patients with advanced cirrhosis are more likely to develop esophageal varices. The severity of liver disease is correlated with the grade of esophageal varices. About 45% of patients with Child-PughA cirrhosis have varicose veins (Elsebaey et al., 2019), while 85% of patients with Child-PughC cirrhosis have varicose veins (Sousa et al., 2017). Patients with cirrhosis of the liver have a higher incidence of upper gastrointestinal bleeding if they have bad lifestyle habits such as smoking and drinking.
Liver cirrhosis and infection
Patients with cirrhosis are prone to co-infection, which is one of the common causes of death in patients with cirrhosis. Related studies have confirmed that 39.7% of patients with cirrhosis can be complicated by various infections (Fernández et al., 2019). Piano et al. (2021) found through their research that the infection rate of hospitalized patients with cirrhosis was high, which was 4–5 times that of normal population, and the infection rate of patients with decompensated cirrhosis was up to 67%. Liver cirrhosis complicated with infection is also prone to septic shock, which can lead to multiple organ failure, leading to liver dysfunction, liver cell damage, and eventually liver failure and death (Hsu et al., 2021). Multiple mechanisms are involved in the co-infection of cirrhosis. First of all, the liver is closely related to the body’s immunity. Patients with cirrhosis have low liver reserve function, and their innate and acquired immune defense capabilities as well as the ability to remove microorganisms and toxins are severely impaired. Clinically, cirrhosis may be characterized by increased susceptibility to infection and poor prognosis after complicated with sepsis (Lebossé et al., 2019; Basho et al., 2021). Secondly, the characteristic clinical manifestation of decompensation in cirrhosis is portal hypertension. Anatomically, blood flow from the internal organs and intestines is connected to the portal vein, which enables bacteria in the intestine to enter the systemic circulation blood system through the collateral branches of the portal vein circulation and cause systemic infection (Tripathi et al., 2018; Solé et al., 2021). Another possibility is that portal hypertension in cirrhosis may show the characteristics of spleen enlargement in the early stage, and the occurrence of spleen enlargement may be accompanied by hypersplenism, which will further affect the immune function of the body, thus aggravating the development of liver cirrhosis (Asanoma et al., 2014).
Liver cirrhosis and hepatopulmonary syndrome
Hepatopulsyndrome (HPS), first proposed by Knudson and Kennedy in 1977 (Kennedy and Knudson, 1977), is a clinical syndrome characterized by arterial oxygenation dysfunction due to dilation of blood vessels in the lung, characterized by dyspnea in upright position and dyspnea after movement (Weinfurtner and Forde, 2020). HPS is most common in patients with cirrhosis, and can also be seen in acute and chronic hepatitis, acute liver failure, etc., which is one of the common complications of chronic liver disease (Machicao et al., 2014). One study (Fallon et al., 2008) found that non-HPS patients with a similar degree of cirrhosis were only half as likely to die as those with HPS. Epidemiological studies have also shown that the incidence of HPS in adults with end-stage liver diseases such as cirrhosis ranges from 4% to 47% (Varghese et al., 2007), while the prevalence of HPS in all patients with cirrhosis is 20% (Møller et al., 2009). The prevalence of HPS in patients with cirrhosis requiring liver transplantation is about 5%–30% of the population (Rodríguez-Roisin and Krowka, 2008). Modern medicine has also found that the pathogenesis of HPS may be related to the release of various cytokines in the body resulting in angiogenesis and pulmonary vasodilation caused by cirrhosis. As a serious pulmonary complication of end-stage liver disease, HPS seriously affects the quality of life and prognosis of patients. When dyspnea and hypoxemia occur in patients with chronic liver disease or portal hypertension, attention should be paid to screening whether HPS is combined, so as to achieve early detection, diagnosis and treatment to prevent deterioration of the condition.
Liver cirrhosis and hepatorenal syndrome
Hepatorenal syndrome (HRS) is a serious complication mainly manifested by renal injury in patients with severe liver diseases such as cirrhosis combined with ascites (Meola et al., 2016). Nowadays, with the deepening of HRS research, great progress has been made in pathogenesis and treatment. The International Club of Ascites (ICA) proposed the concept of acute kidney injury (AKI). On this basis, the diagnostic criteria and treatment guidelines of the HRS were revised (Angeli et al., 2015). Nowadays, with the deepening of HRS research, great progress has been made in pathogenesis and treatment. Studies (Al-Khafaji et al., 2015) have shown that 35%–40% of patients with cirrhosis combined with ascites may develop HRS. The main risk factors of HRS include portal hypertension, sepsis caused by spontaneous peritonitis, and cardiac insufficiency is also a high risk factor for HRS (Lenz et al., 2014). At present, global scholars have not fully understood the pathogenesis of HRS. Existing studies have found that due to the influence of end-stage liver diseases such as cirrhosis, the inactivation of vasodilator factors in vivo is reduced, which leads to the dilation of visceral and peripheral arteries, the contraction of renal vessels, the reduction of glomerular filtration rate and the decrease of renal blood flow, and finally the occurrence of HRS (Sobhonslidsuk, 2015; Simonetto et al., 2020; Wu et al., 2024). At the same time, liver inflammation, intestinal flora displacement and concurrent infection caused by cirrhosis lead to the release of a large number of inflammatory factors and endotoxemia, causing renal microcirculation dysfunction, which can induce renal function injury (Rad et al., 2024).
Liver cirrhosis and primary liver cancer
Primary liver cancer, as a high incidence of human malignant tumor, lacks typical clinical symptoms in the early stage, but the disease progresses rapidly, has a high risk of death, and the prognosis of patients is generally poor. Liver cirrhosis is a major risk factor for liver cancer and hepatology-related death. Therefore, accurate evaluation of the severity of cirrhosis is of great significance for clinical monitoring efficacy and prognosis assessment (Ren et al., 2017). Modern medical research has found that patients with cirrhosis with a genetic history of primary liver cancer have a significantly increased risk of developing primary liver cancer. Previous studies have found that the incidence of cirrhosis complicated with liver cancer is 1.5–6 percent per year (Bruix et al., 2011), and this figure may be increasing. Therefore, the prevention of primary liver cancer is urgent. More studies have found that long-term excessive drinking can increase the risk of liver cirrhosis complicated with primary liver cancer, especially after hepatitis B virus attacks the human liver, alcohol will cause increased liver burden, resulting in liver damage, and ultimately accelerate the occurrence and development of liver cancer. While avoiding excessive drinking for a long time, all countries should also strengthen health education about liver cirrhosis and primary liver cancer, improve patients’ further understanding of liver cirrhosis and primary liver cancer, enhance patients’ awareness of prevention and treatment, and reduce the incidence of liver cirrhosis complicated with primary liver cancer.
Research on liver cirrhosis and its complications underscores the significant impact of these conditions on patient prognosis and quality of life. While there are advancements in understanding risk factors and pathogenesis, challenges remain in the form of high variability in incidence rates, limited understanding of mechanisms, and the need for more effective management and preventive strategies. Further research is essential to address these gaps and improve patient outcomes.
Treatment of liver cirrhosis using modern medicine
Non-drug treatment
First of all, cirrhosis patients should maintain a reasonable diet. One study (Yao et al., 2018) found that the development of cirrhosis is associated with significant nutritional risks, often resulting in poor survival and serious complications. Dietary therapy is an important component of the treatment regimen for cirrhosis (Iwasa et al., 2013). Malnutrition affects 25 to 56 percent of patients with cirrhosis (Guglielmi et al., 2005; Huynh et al., 2015) and 65 to 90 percent of patients with advanced cirrhosis (Henkel and Buchman, 2006). Therefore, patients with cirrhosis should receive early nutritional interventions high in energy, carbohydrates, and protein, and eat multiple meals daily to ensure adequate nutrition.
Secondly, patients with cirrhosis should also maintain reasonable living habits, such as healthy work and rest time, and maintain a good mental state. Adequate sleep is essential for people, and studies (Marjot et al., 2021) have also found that problems such as lack of sleep are closely related to the pathogenesis of chronic liver disease. In conclusion, good living habits also play a very important role in the treatment and prognosis of cirrhosis.
Exercise therapy for liver cirrhosis has also received extensive attention from scholars. Exercise rehabilitation therapy is one of the important means of chronic disease conditioning. The American Association for the Study of Liver Disease recommends individualized exercise rehabilitation for patients with cirrhosis (Chen and Dunn, 2018). Another study (Ney et al., 2017) found that exercise levels were generally low in patients with cirrhosis, with 76% spending most of their time in a sitting position, which is detrimental to recovery from liver disease. In daily life, proper scientific exercises such as Tai Chi, five animal boxing/exercise, and eight trigrams boxing can effectively improve heart and lung function and prevent the occurrence of alcoholic fatty liver disease and cirrhosis.
Non-drug treatments for cirrhosis, including dietary therapy, healthy living habits, and exercise, offer significant benefits for patient outcomes. Proper nutrition and individualized exercise programs are crucial, though adherence to these regimens can be challenging. Further support and personalized plans are essential to maximize the effectiveness of these non-drug treatments.
Drug treatment
After the diagnosis of liver cirrhosis is clear, comprehensive treatment should be started as soon as possible. In the treatment of cirrhosis, first attention should be paid to the etiological treatment, anti-inflammatory and anti-hepatic fibrosis treatment if necessary, and active prevention and treatment of complications. i) The key to the treatment of cirrhosis is etiological treatment. For example, all patients with cirrhosis who are positive for viral surface antigen should be evaluated for antiviral therapy, and patients should be treated with antiviral drugs, with the aim of delaying the progression of cirrhosis and reducing the incidence of liver cancer by inhibiting the replication of the virus (Manolakopoulos et al., 2009). Today, antiviral drugs include interferon, nucleoside and nucleotide drugs, such as Entecavir and tenofovir. One study (Marcellin et al., 2013) found that in 96 patients with HBV-associated cirrhosis followed up for 5 years after treatment with tenofovir dipivoxil, cirrhosis reversed in 71 patients, with a cure rate of 74 percent. It has also been found that treatment with standard antiviral drugs significantly increases the rate of sustained virological response and significantly reduces the recurrence rate of HCV (Morgan et al., 2010). In addition, a related antiviral agent, Adefovir dipivoxyl, has been found to be the antiviral strategy of choice for the treatment of hepatitis B-induced decompensated cirrhosis (Zhang et al., 2017). And there is also a prospective new study (Jagst et al., 2024) that found that hepatitis E tends to convert to chronic infection in immunocompromised patients, and that sofosbuvir is effective in inhibiting hepatitis E virus replication, especially in extrahepatic neuronal cells. ii) Anti-inflammatory and anti-fibrosis therapy should be considered in some patients with cirrhosis for whom etiological therapy is not available, or for whom liver inflammation or fibrosis remains severe after etiological therapy. Commonly used liver protection anti-inflammatory drugs are silymarin, glycyrrhizic acid preparations, polyene phosphatidylcholine, adenosine methionine, dicycloalcohol, reduced glutathione, ursodeoxycholic acid (UDCA) and so on. These hepatoprotective and anti-inflammatory drugs can inhibit liver inflammation, detoxify, regulate energy metabolism, remove reactive oxygen species and free radicals, improve the stability of liver cell membrane, immune regulation, integrity and fluidity, and ultimately achieve the purpose of reducing liver damage, reducing intrahepatic cholestasis, and promoting liver cell repair and regeneration (Damiris et al., 2020; Guo and Lu, 2020). Apart from this, the main antifibrotic drugs are Losartan (Gu et al., 2023) and Hydronidone. Recent studies (Sun et al., 2024) have also found that Hydronidone is able to induce apoptosis in activated HSC through the mitochondrial apoptotic pathway. iii) For the prevention and treatment of complications of liver cirrhosis, such as ascites, hepatic encephalopathy, etc. First-line ascites treatment includes: limiting salt intake and rational application of furosemid, spironolactone and other diuretics. A recent case report found that the optimal diuretic regimen for patients with hepatic pleural effusions may be furosemide in combination with spironolactone, yet this regimen was ineffective in about one-quarter of patients, requiring treatment such as thoracentesis (Malick et al., 2023). Second-line treatment includes rational application of vasoconstricting active drugs and other diuretics, such as tovaptan (Pratama et al., 2024) and terivasopressin (Ding et al., 2024); third-line treatment includes renal replacement therapy, ascites concentrated transfusion and liver transplantation. For the treatment of hepatic encephalopathy, the main treatment methods should be to correct the imbalance of amino acids, reduce the production of ammonia, promote the discharge of ammonia, reduce the absorption of enterotoxin, and maintain intestinal cleanliness. Also, rifaximin and lactulose/lactitol can be selected as the first line of treatment (Rajpurohit et al., 2022).
Drug treatments for liver cirrhosis, including etiological, anti-inflammatory, and anti-fibrosis therapies, as well as treatments for complications, offer significant benefits in managing the disease and improving patient outcomes. However, limitations such as variable patient responses, potential side effects, and the need for individualized treatment plans highlight the ongoing challenges in treating liver cirrhosis effectively. Further research and development of new therapies are needed to address these challenges and improve the long-term prognosis for patients with cirrhosis.
Treatment of liver cirrhosis in traditional Chinese medicine
Chinese medicine decoction
Yinchenhao decoction
Yinchenhao decoction (YCHD) is a Chinese medicine widely used in clinics to treat cirrhosis. Jiang et al. (2015) found that YCHD could significantly reverse changes in the expression of immunoregulatory genes in liver tissue, increase serum albumin level, effectively reduce the activity of serum alanine amino transportase, and reduce the degree of liver inflammation and necrosis. These changes were related to the regulation of the expression of genes related to immune/inflammatory response. Additionally, YCHD did not cause spleen weight loss or hepatocyte degeneration in mice. Cai et al. (2019) identified 45 key active ingredients and 296 potential therapeutic targets for YCHD anti-liver fibrosis through transcriptomic and network pharmacological analysis, indicating that YCHD mainly acts on apoptosation-related signaling pathways. In vivo experiments confirmed that YCHD treatment reduced the apoptosis of liver parenchymal cells and alleviated the symptoms of liver fibrosis. Further research by Cai et al. (2018) demonstrated that YCHD inhibits the activation and proliferation of HSCs through the TGF-β1/Smad/ERK signaling pathway. Liu et al. (2008) conducted a controlled experimental study on a variety of traditional prescriptions for cirrhosis and found that YCHD most significantly inhibited α-SMA activation and regulated rat cirrhosis. A systematic review and meta-analysis by Shi et al. (2021) provided high evidence that YCHD has a favorable modulatory effect on cholestasis, delaying the onset and progression of cirrhosis.
Xiaochaihu decoction
Xiaochaihu Decoction (XCHD), derived from Shanghan Zabing Lun, is a multi-functional classic decoction for treating a variety of diseases. Qiang et al. (2022) identified 164 key compounds of XCHD and 95 core targets of regulating liver fibrosis. They found that XCHD prevents liver cirrhosis by regulating several key pathways such as the TNF, IL-17, and PI3K-Akt signaling pathway. Huang et al. (2020) found that XCHD significantly inhibits the upregulation of Hsp47, TGF-β1, Col1A1, α-SMA, etc., mediating the HSP47/TGF-β axis to protect the liver. Wang et al. (2023a) found that XCHD significantly alleviated liver fibrosis in a mouse model, improving liver function, reduction liver collagen accumulation, and inhibition of HSC activation. Besides chronic liver diseases, XCHD is also widely used in clinical practice for its regulatory effects on common mental disorders such as depression (Sun et al., 2023).
Huangqi decoction
Huangqi decoction (HQD) has been used for the preventing and treating hepatic fibrosis and cirrhosis since ancient times. Zhang et al. (2015) found that HQD significantly downregulated the expression of PDGFrb, PDGFra, PDGFd, PDGFb, THBS1, COL1A1, COL1A2, and COL5A2 in rat liver fibrosis, and downregulated PDGF and TGF-β signaling pathways, thus treating cirrhosis. Liu et al. (2012) found that HQD promotes CD68 expression in liver fibrosis development and protects against liver cell apoptosis. Wang et al. (2021) identified various active components in HQD for liver fibrosis using a pharmacokinetics-based strategy, which was validated in the CCl4-induced mouse liver fibrosis model. Dong et al. (2023) found that HQD adjusted the LCC-C18ORF26-1/miR-663a/TGF-b1/TGF-bRI/p-Smad2 axis to inhibited HSCs activation and proliferation, preventing liver cirrhosis. HQD also alleviates biliary fibrosis and chronic cholestatic liver injury by inhibiting the NF-κB pathway and inducing the Nrf2 pathway in a chronic cholestatic mouse model, preventing liver cirrhosis onset and exacerbation (Li et al., 2019).
Dahuang Zhechong pill
The traditional prescription Dahuang Zhechong pill (DHZCP), consisting of rhubarb, native turtle worm, leech, tabanus worm, scutellaria baicalensis, and peach kernel, promotes blood circulation, Gong et al. (2018) found that DHZCP inhibits p-Erk and regulates other factors to inhibit p-p38 by increasing the expression of growth arrest specific 5 (GAS5), alleviating liver fibrosis and preventing cirrhosis. Another study by Gong et al. (2020) found that DHZCP prevents cirrhosis in animal models by inactivating the PI3K/Akt pathway, protecting the liver from damage. Fu et al. (2023) found that DHZCP improves hepatic sinusoids’ capillaries by inhibiting the MK/Itgα signaling pathway, delaying disease progression. Key active molecules affecting this pathway include Liquiritin, Naringenin, Rhein, and PMEG. A systematic review and meta-analysis found that DHZCP reduces the serum biomarkers of liver fibrosis in chronic hepatitis B patients (Wei et al., 2015). Combining Entecavir and DHZCP is an effective intervention for cirrhosis, with an optimal treatment course of about 6 months (Ye et al., 2022). He et al. (2024) recently found that DHZCP effectively regulates the enterohepatic axis, improving intestinal barrier integrity by regulating metabolites and intestinal flora, ultimately inhibiting liver fibrosis progression.
Xiayuxue decoction
Xiayuxue decoction (XYXD) came from Jingui Yaolue. Zhang et al. (2020) prepared different fractions including ethyl acetate fraction (EF) from XYXD. It was found that the potential mechanism of EF prevention of liver cirrhosis may be related to the induction of apoptosis of HSCs. Ma et al. (2017) believe that enterogenic endotoxin plays an important role in the further development of liver fibrosis, and experimental studies have confirmed that XYXD treatment can significantly improve CCl4-induced cell death and intestinal inflammation, indicating that XYXD can inhibit the further development of liver fibrosis by improving intestinal epithelial damage. In addition to interfering with the progression of liver cirrhosis, another study (Liu et al., 2015) found that XYXD can also promote the apoptosis of macrophages in rats with renal histopathological damage caused by liver cirrhosis, thus reducing kidney damage in rats. A recent pharmacological study (Deng et al., 2024) also found that XYXD was able to exert significant anti-HCC effects by modulating the interaction between bile acids and intestinal flora, ultimately triggering the immune action of NKT cells against HCC.
Yiguanjian decoction
As a more commonly used classical prescription, Yiguanjian (YGJ) decoction is widely used clinically to treat liver disease, which mainly consists of rehmannia, Radix saphora, Angelica, ophiopogon, and wolfberry. Related studies (Tian et al., 2016) found that YGJ was able to increase the expression of MTH1 and Bax, decrease the expression of TNF-α, and significantly improve the degree of hepatic inflammation and fibrosis in mice with chronic hepatitis in a mouse model of hepatic injury, and ultimately was able to inhibit DNA damage in mice with immune liver damage. Relevant researchers (Zhou et al., 2015) found that YGJ and its main component iYGJ can inhibit liver angiogenesis in cirrhotic mice by inhibiting the HIF-1α/VEGF signaling pathway, and finally confirmed that its anti-angiogenesis effect is closely related to improving the liver hypoxic microenvironment. Xu et al. (2018) also established a liver cirrhosis rat model and treated the liver cirrhosis rats with YGJ, and found that YGJ can enhance the liver cirrhosis repair of FLSPC-mediated by regulating the activation state of macrophages, and finally confirmed that YGJ combined with stem cell transplantation is one of the main methods for the treatment of end-stage liver cirrhosis. Through more in-depth studies, Wang et al. (2012) confirmed that YGJ can also inhibit the transfer of bone marrow cells to the liver, further inhibit the differentiation of bone marrow cells, inhibit the proliferation of hepatocytes and progenitor cells in the injured liver, and ultimately play a role in the treatment of liver fibrosis and fundamentally prevent the formation of cirrhosis. Some scholars (Xu et al., 2021) also believe that YGJ can regulate the state of macrophages, and the main anti-cirrhosis effect of YGJ is related to its ability to inhibit the polarization of macrophages M1.
Other prescriptions
Kangxian ruangan (KXRG) capsule is a classic homemade prescription. It is composed of seven Chinese medicines, including salvia miltiorrhiza, red peony root, bupleurum, and turtle shell. It has the key role of supplementing the spleen and warming Yang. Clinically, it can significantly reduce or even reverse liver fibrosis and prevent the development of liver cirrhosis. Relevant scholars (Liu et al., 2018) have conducted experimental studies on KXRG and found that it can effectively alleviate liver fibrosis, histopathological changes, and inflammation in rats, and further relieve liver inflammation by maintaining the balance of TNF-α/IL-10, positively regulate the balance of Bcl-XL/Bax or Bcl-2/Bax, and activate damaged liver cells. It can alleviate the progression of nonalcoholic fatty liver disease from liver fibrosis to cirrhosis. As one of the clinical experience prescriptions for the treatment of cirrhosis, KXRG has a remarkable effect, which lays a foundation and provides a direction for the treatment of cirrhosis by modern Chinese medicine in the future.
Chinese medicine decoctions show promise in treating liver cirrhosis by reducing inflammation, improving liver function, and preventing fibrosis. However, studies often have small sample sizes, lack standardized protocols, and offer limited long-term data. Most research is regionally confined to China, requiring broader validation to confirm efficacy and safety globally.
Chinese patent medicine
An-Luo-Hua-Xian
An-Luo-Hua-Xian pill (ALHX) is one of the commonly used Chinese patent medicine for the treatment of liver cirrhosis. As a patented medicine, it has been used in China for more than 15 years. It has the effects of invigorating spleen and nourishing liver, nourishing blood and promoting blood circulation, and softening and dispersing masses. In clinical practice, it is mainly used for chronic hepatitis B and early and middle stage cirrhosis after hepatitis B, and has achieved good curative effect. A clinical study (Liu et al., 2023) of 780 patients found that ALHX combined with Entecal can significantly improve liver fibrosis in patients with chronic hepatitis B and prevent further progression to cirrhosis, so the clinical study to some extent confirmed the positive effect of ALHX in the treatment of liver disease. Xiao and many other researchers (Xiao et al., 2022) conducted a randomized controlled trial that confirmed that chronic hepatitis B patients with F ≤ 2 and alanine aminotransferase (ALT) < 2ULN treated with ALHX could improve the degree of liver fibrosis after 48 weeks. The results of related meta-analysis also confirmed that ALHX and Entecavir had a significant effect on liver fibrosis or cirrhosis (Song et al., 2019). An earlier study (Huang et al., 2009) also found that ALHX was also effective in alleviating liver fibrosis caused by schistosomiasis and further confirmed its excellent hepatoprotective and antifibrotic effects.
Fuzhenghuayu
Fuzhenghuayu (FZHY) Decoction is also one of the Chinese patent medicines used to treat cirrhosis clinically, many important components of which are compounds extracted from natural plants. Now, the effect of Fuzhenghuayu (FZHY) decoction has been further proved in clinical studies and experiments. Liu et al. (2019) found that FZHY not only alleviates liver fibrosis and impedes its further progression to cirrhosis, but also improves vascular remodeling in mouse models. Song et al. (2018) recruited 113 subjects, including 63 cirrhosis patients and 50 healthy controls, and applied FZHY to their intervention. The curative effect evaluation showed that the liver stagnation syndrome (LSS) and liver-kidney Yin deficiency syndrome (LKYDS) were effective. The metabolic mechanism may be related to the improvement of the LSS energy supply and the enhancement of the LKYDS detoxification function. Another multi-center clinical study (Liu et al., 2005) found that FZHY can significantly reduce inflammation score and mean inflammatory activity, and has a very good therapeutic effect on chronic hepatitis B-induced liver fibrosis, and the efficacy is better than the Heluoshugan capsule. In addition, Hu et al. (2019) confirmed through animal experiments that FZHY can rapidly upregulate the expression of metabolic enzymes such as Gpt, Adh1, and Hk2, downregulate the expression of Acss2 and Gs, and can also improve rat liver fibrosis and prevent the occurrence of cirrhosis by changing metabolic pathways. Chen et al. (2016) also identified major biomarkers for evaluating the efficacy of FZHY in the treatment of cirrhosis caused by chronic hepatitis B based on transcriptional profiling and miRNA-target network analysis. A miRNA panel with -326, -1182, hsa-miR-18a-5p and -193b-5p were established.
Biejia-ruangan
In recent years, Biejia-Ruangan (BR) has been approved as an anti-fibrotic Chinese medicine for the treatment of chronic liver disease and has good efficacy in the prevention and treatment of cirrhosis. A double-blind randomized controlled trial (Ji et al., 2022) has shown that BR combined with entecavir significantly reduces the risk of hepatogenic death and liver cancer in patients with chronic viral hepatitis B and cirrhosis. Another similar study (Rong et al., 2022) also found that in chronic hepatitis B patients with cirrhosis, adding BR to the current standard treatment can help better improve liver fibrosis and alleviate clinical symptoms. Yang et al. (2013) also found in relevant experimental studies that BR can significantly inhibit the progression of liver fibrosis in vitro and in vivo, and its main mechanism of action may be closely related to the downregulation of fibrosis signal transduction in the TGF-β-Smad pathway. A meta-analysis (Meng et al., 2022) of 26 studies involving 2,717 patients showed that BR significantly improved liver function alleviated the degree of liver fibrosis, and prevented the occurrence of cirrhosis. Interestingly, one study (Luo et al., 2023) also explored the relationship between BR compound and incidence of HCC, but the exact effect and mechanism of action are not fully understood, and more work or scientific studies are still needed to elucidate the clinical effects of BR in the future. To summarize, the efficacy of using Chinese medicine therapies in the treatment of liver cirrhosis is remarkable and has a wide range of application prospects, which is worthy of our further in-depth excavation and exploration.
Chinese patent medicines such as ALHX, FZHY and BR have shown promise in treating liver cirrhosis by improving liver fibrosis, reducing inflammation, and preventing disease progression. However, limitations include small sample sizes, variability in protocols, and a need for larger, rigorous trials to understand their mechanisms and long-term effects. Most studies are limited to China, requiring broader validation. Studies related to the treatment of cirrhosis by Chinese medicine are shown in Table 1. Comparison of drug/medicine selection and efficacy in the treatment of liver cirrhosis between Western or Chinese medicine is shown in Table 2.
Table 1. Studies related to the treatment of liver cirrhosis with Chinese medicine.
Table 2. Drug/medicine selection and efficacy in the treatment of cirrhosis by Western or Chinese medicine.
Acupuncture treatment
The ancient practice of acupuncture is gaining popularity around the world. More than 30 years ago, the World Health Organization began recommending acupuncture therapy. Another decade later, the NIH in the United States also reached a consensus on the effectiveness of acupuncture therapy. As an effective non-pharmacological treatment to reduce the symptoms of cirrhosis, it can be used as an alternative or complementary treatment to improve the efficacy of medication, and compared with medication, acupuncture has the advantages of low cost, low side effects and quick results. Recent studies (Wang et al., 2023b) have found that acupuncture also has a significant immunomodulatory effect, playing a key role in regulating the innate immune system, adaptive immune system, etc. It is effective in regulating the body’s physiological functions through the stimulation of specific body points. Acupuncture therapy is gradually entering the mainstream medical system. In general, “the position of acupuncture feeling, the position of disease response, and the location of therapeutic effect” are the three major functions of acupuncture points, and they are also the basic points for understanding the principle of acupuncture action, which is worthy of in-depth study by our later generations. Nowadays, acupuncture not only has a good regulation effect on the complications of cirrhosis but also has a good effect on the treatment and prevention of cirrhosis. Zhang et al. (2012a) found through the experimental study that acupuncture can significantly improve the therapeutic effect of curcumin on CCl4-induced liver fibrosis in rats, and effectively reduce the levels of serum aspartate aminotransferase (AST), ALT, and hyaluronic acid. Other researchers (Zhang et al., 2012b) have also found that the combination of acupuncture and curcumin in the treatment of liver fibrosis significantly enhances the effect of curcumin at the molecular level, the main mechanism of action is that it stimulates the degradation of the ECM in the fibrotic liver and the destruction of the PDGF-βR/ERK pathway. Other relevant literature (Zhou et al., 2012) has found that acupuncture has potential advantages in the prevention of cirrhosis because acupuncture can better reduce the body’s qi and blood stasis and enhance the body’s immunity. The results of the meta-analysis (Qi et al., 2020) also show that acupuncture is an important treatment choice for patients with cirrhosis as a complementary therapy.
Acupuncture has gained global acceptance as a low-cost, effective treatment for cirrhosis, endorsed by the WHO and NIH. It offers immunomodulatory benefits and enhances treatments like curcumin for liver fibrosis. However, research is often limited by small sample sizes, lack of rigorous controls, unclear long-term effects, and variability in techniques, necessitating broader validation.
Combination of Chinese and Western medicine in the treatment of liver cirrhosis
At present, the treatment of liver cirrhosis with integrated traditional Chinese and Western medicine is widely popular in China, supported by substantial related research. Regarding ascites in cirrhosis, a recent experimental study found that combining YCHD with spironolactone can prevent sodium-potassium imbalance, providing significant guidance for managing ascites in liver cirrhosis (Hsueh and Tsai, 2023). For chronic hepatitis B cirrhosis, a clinical study involving 116 patients demonstrated that the group treated with both Chinese medicine and Western medicine showed superior results compared to the control group. Specifically, the combined treatment group exhibited better outcomes in terms of ALT, AST, total bilirubin, alpha-fetoprotein levels, coagulation function indicators, liver elasticity values, and overall efficacy. Additionally, the incidence of complications such as spontaneous bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding, and electrolyte imbalance was significantly lower in the combined treatment group. The authors concluded that integrating Chinese medicine and Western medicine in the treatment of cirrhosis can effectively reduce complications, improve clinical symptoms, and enhance clinical efficacy, making it worthy of further research and clinical application (You et al., 2023). In another prospective randomized controlled trial on hepatitis B cirrhosis, it was found that the antiviral entecavir combined with Fuzheng Huayu tablets improved the biochemical response rate and showed trends towards improving HBeAg seroconversion and liver fibrosis rates, compared to the control group (entecavir plus a placebo). Importantly, no serious adverse events related to the study treatment were observed during the trial (Cheng et al., 2022). Regarding primary biliary cholangitis, Chinese scholars conducted a systematic review and meta-analysis of randomized controlled trials on the combined treatment of Chinese medicine and UDCA. The findings confirmed that Chinese medicine adjunctive therapy with UDCA had significant advantages over UDCA alone. Specifically, Guishao Huoxue (GSHX) decoction combined with UDCA was beneficial for the clinical efficacy rate, while ALHX pill combined with UDCA had more comprehensive effects on liver function indicators such as alkaline phosphatase and TBil (Chen et al., 2020).
These findings collectively highlight the potential benefits of integrating traditional Chinese and Western medicine in the treatment of liver cirrhosis, warranting further research and clinical promotion. However, current research on this integrated approach has several limitations. These include limited sample sizes, potential biases due to study design issues, unclear long-term effects, inadequate reporting of adverse effects, insufficient mechanistic research, regional limitations with most studies conducted in China, and variability in treatment methods and dosages, which affect the reproducibility and comparability of results.
Future drug treatments should focus on multi-target combination therapies to enhance efficacy and reduce side effects. The development of new antifibrotic drugs, such as RNA interference and gene editing technologies (Rajput et al., 2021), will be a key research focus. Further high-quality evidence-based studies are required to validate the efficacy and safety of integrating Chinese and Western medicine. Personalised treatment, guided by genomics and other omics technologies, will tailor therapies to individual patients, improving outcomes and reducing adverse effects (Park et al., 2022; Yang et al., 2023). The integration of nanotechnology and biomaterials will facilitate the development of more effective drug delivery systems, ensuring a more precise targeting of diseased areas. Immunomodulatory drugs and a comprehensive approach to lifestyle management will also play a pivotal role in future strategies, collectively improving patient prognosis. By integrating innovation, personalisation, and advanced delivery systems, liver cirrhosis treatment will continue to evolve and optimise.
Conclusions and perspective
After continuous research and exploration, research related to liver cirrhosis has achieved certain results. Modern medicine mainly believes that viral hepatitis, non-alcoholic fatty liver disease, and other related etiologies promote the occurrence and development of cirrhosis, while the pathogenesis of cirrhosis is closely related to the activation of HSC and the regulation of LSECs. At present, the treatment of liver cirrhosis in Western medicine is mostly based on etiologic treatment, anti-inflammatory and antifibrotic treatment, as well as prevention and treatment of cirrhosis complications, which cannot be completely cured. However, Chinese medicine is widely used in the treatment of liver fibrosis, cirrhosis, and its related complications, based on the characteristics of multi-component, multi-target, multi-pathway, and the combination of holistic and local treatment of cirrhosis, which has achieved good therapeutic effects in the clinic and greatly enriched the prevention and treatment means of chronic liver diseases in the clinic (Li 2020; Pun et al., 2024). Chinese medicine is a treasure of Chinese traditional culture. In-depth excavation of the key target links of traditional Chinese medicine interventional therapies, such as Chinese medicine monomer, Chinese medicine decoction, Chinese patent medicine as well as acupuncture, closely integrates the theoretical thinking of Chinese medicine with modern medicine and provides brand-new ideas and better therapeutic strategies for the treatment of liver cirrhosis and other chronic liver diseases.
The integration of Western and Chinese Medicine in the treatment of cirrhosis is a complex landscape. Current treatments in Western medicine, while effective in managing symptoms and complications, often fail to completely halt disease progression. Chinese medicine offers a holistic approach with multi-target strategies, including herbal decoctions and acupuncture, which have shown promise in reversing liver fibrosis and improving overall liver function. However, there is a grey area where the lack of standardised treatment protocols and comprehensive clinical trials creates challenges in validating the efficacy of Chinese medicine within the framework of Western medicine. To fill these gaps, rigorous scientific studies are needed, including high-quality multicentre clinical trials and advanced pharmacological research to elucidate the mechanisms behind Chinese medicine therapies. Future developments should focus on creating integrative treatment protocols that leverage the strengths of both medical systems, ultimately improving patient outcomes and advancing the understanding of cirrhosis management.
However, despite the progress made, several limitations persist in current research. Firstly, there is a dearth of animal models that effectively integrate Chinese medicine theories, basic experiments, and clinical observations. Future research endeavors should thus strive for innovative approaches that align closely with the principles of Chinese medicine. Secondly, existing Chinese medicine research on cirrhosis predominantly relies on animal experimentation, resulting in a limited evidence chain and insufficiently detailed mechanistic insights. Future efforts should aim to deepen our understanding of the mechanisms underlying Chinese medicine interventions for cirrhosis, employing diverse research methodologies to strengthen the evidence base. Moving forward, there is a pressing need to undertake high-quality, multicenter, large-scale, and standardized clinical evidence-based research, integrating it with collaborative basic experiments. This approach aims to facilitate the translation of Chinese medicine-related research outcomes into clinical practice. Furthermore, it remains imperative to leverage the distinctive advantages of Chinese medicine in preventing and treating cirrhosis and other chronic liver diseases. Harnessing the creativity and distinctiveness of Chinese medicine, deeper exploration into the molecular mechanisms underlying Chinese medicine’s therapeutic effects is warranted. This exploration should lead to the development of novel proprietary Chinese medicines and their judicious combination with Western medicines, thereby enhancing the quality of diagnosis and treatment for cirrhosis patients. Simultaneously, it is essential to perpetuate and elevate the heritage of Chinese medicine culture. It is my belief that in the future, we will achieve groundbreaking discoveries akin to Artemisinin and make significant contributions to the field of human medicine.
Author contributions
SZ: Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing–original draft, Writing–review and editing. CX: Data curation, Writing–review and editing. SL: Data curation, Supervision, Writing–review and editing. XZ: Supervision, Writing–review and editing. XL: Methodology, Writing–review and editing. QL: Data curation, Writing–review and editing. XC: Data curation, Methodology, Writing–review and editing. WW: Conceptualization, Data curation, Writing–review and editing. WQ: Data curation, Writing–review and editing. HD: Formal Analysis, Supervision, Writing–review and editing. PZ: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Project administration, Resources, Software, Supervision, Validation, Writing–review and editing. YY: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing–review and editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (Grant No. 82104810), Science, Technology and Innovation Specialization 2023 (Grant No. DZMKJCX-2023-014) and Changjiang Scholars Special Posting Programme (Grant No: ZYS-2021CJ01).
Acknowledgments
The material in all the pictures of this article was provided friendly by Figdraw.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Al-Khafaji, A., Nadim, M. K., and Kellum, J. A. (2015). Hepatorenal disorders. Chest 148 (2), 550–558. doi:10.1378/chest.14-1925
Angeli, P., Gines, P., Wong, F., Bernardi, M., Boyer, T. D., Gerbes, A., et al. (2015). Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut 64 (4), 531–537. doi:10.1136/gutjnl-2014-308874
Asanoma, M., Ikemoto, T., Mori, H., Utsunomiya, T., Imura, S., Morine, Y., et al. (2014). Cytokine expression in spleen affects progression of liver cirrhosis through liver-spleen cross-talk. Hepatol. Res. 44 (12), 1217–1223. doi:10.1111/hepr.12267
Asrani, S. K., Devarbhavi, H., Eaton, J., and Kamath, P. S. (2019). Burden of liver diseases in the world. J. Hepatol. 70 (1), 151–171. doi:10.1016/j.jhep.2018.09.014
Asrani, S. K., Larson, J. J., Yawn, B., Therneau, T. M., and Kim, W. R. (2013). Underestimation of liver-related mortality in the United States. Gastroenterology 145 (2), 375–382. doi:10.1053/j.gastro.2013.04.005
Bartolotta, T. V., Randazzo, A., Bruno, E., and Taibbi, A. (2022). Focal liver lesions in cirrhosis: role of contrast-enhanced ultrasonography. World J. Radiol. 14 (4), 70–81. doi:10.4329/wjr.v14.i4.70
Basho, K., Zoldan, K., Schultheiss, M., Bettinger, D., Globig, A. M., Bengsch, B., et al. (2021). IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis. J. Hepatol. 74 (3), 649–660. doi:10.1016/j.jhep.2020.10.012
Biecker, E. (2011). Diagnosis and therapy of ascites in liver cirrhosis. World J. Gastroenterol. 17 (10), 1237–1248. doi:10.3748/wjg.v17.i10.1237
Bossen, L., Ginès, P., Vilstrup, H., Watson, H., and Jepsen, P. (2019). Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascites. J. Gastroenterol. Hepatol. 34 (5), 914–920. doi:10.1111/jgh.14558
Bruix, J., and Sherman, M.American Association for the Study of Liver Diseases (2011). Management of hepatocellular carcinoma: an update. Hepatology 53 (3), 1020–1022. doi:10.1002/hep.24199
Cai, F. F., Bian, Y. Q., Wu, R., Sun, Y., Chen, X. L., Yang, M. D., et al. (2019). Yinchenhao decoction suppresses rat liver fibrosis involved in an apoptosis regulation mechanism based on network pharmacology and transcriptomic analysis. Biomed. Pharmacother. 114, 108863. doi:10.1016/j.biopha.2019.108863
Cai, F. F., Wu, R., Song, Y. N., Xiong, A. Z., Chen, X. L., Yang, M. D., et al. (2018). Yinchenhao decoction alleviates liver fibrosis by regulating bile acid metabolism and TGF-β/smad/ERK signalling pathway. Sci. Rep. 8 (1), 15367. doi:10.1038/s41598-018-33669-4
Campana, L., and Iredale, J. P. (2017). Regression of liver fibrosis. Semin. Liver Dis. 37 (1), 1–10. doi:10.1055/s-0036-1597816
Chen, H. W., and Dunn, M. A. (2018). Arresting frailty and sarcopenia in cirrhosis: future prospects. Clin. Liver Dis. Hob. 11 (2), 52–57. doi:10.1002/cld.691
Chen, Q., Wu, F., Wang, M., Dong, S., Liu, Y., Lu, Y., et al. (2016). Transcriptional profiling and miRNA-target network analysis identify potential biomarkers for efficacy evaluation of fuzheng-huayu formula-treated hepatitis B caused liver cirrhosis. Int. J. Mol. Sci. 17 (6), 883. doi:10.3390/ijms17060883
Chen, X., Ma, X., Wang, R., Wang, L., Li, J., Liu, H., et al. (2020). Treatment of primary biliary cirrhosis with ursodeoxycholic acid combined with traditional Chinese medicine: a protocol for systematic review and meta analysis. Med. Baltim. 99 (46), e23107. doi:10.1097/md.0000000000023107
Cheng, D. Y., Zhao, Z. M., Wan, G., Zheng, H. W., Huang, J. Q., Liu, C. H., et al. (2022). Impact of Fuzheng Huayu tablet on antiviral effect of entecavir in patients with hepatitis B cirrhosis. Hepatobiliary Pancreat. Dis. Int. 21 (5), 479–484. doi:10.1016/j.hbpd.2022.03.007
Cheung, K., Lee, S. S., and Raman, M. (2012). Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin. Gastroenterol. Hepatol. 10 (2), 117–125. doi:10.1016/j.cgh.2011.08.016
Costa, A. P. M., da Silva, M., Castro, R. S., Sampaio, A. L. O., Alencar Júnior, A. M., da Silva, M. C., et al. (2022). PAGE-B and REACH-B predicts the risk of developing hepatocellular carcinoma in chronic hepatitis B patients from northeast, Brazil. Viruses 14 (4), 732. doi:10.3390/v14040732
Damiris, K., Tafesh, Z. H., and Pyrsopoulos, N. (2020). Efficacy and safety of anti-hepatic fibrosis drugs. World J. Gastroenterol. 26 (41), 6304–6321. doi:10.3748/wjg.v26.i41.6304
Dango, S., Beißbarth, T., Weiss, E., Seif Amir Hosseini, A., Raddatz, D., Ellenrieder, V., et al. (2017). Relevance of surgery in patients with non-variceal upper gastrointestinal bleeding. Langenbecks Arch. Surg. 402 (3), 509–519. doi:10.1007/s00423-017-1552-2
de Franchis, R.Baveno VI Faculty (2015). Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J. Hepatol. 63 (3), 743–752. doi:10.1016/j.jhep.2015.05.022
Deng, Z., Ouyang, Z., Mei, S., Zhang, X., Li, Q., Meng, F., et al. (2024). Enhancing NKT cell-mediated immunity against hepatocellular carcinoma: role of XYXD in promoting primary bile acid synthesis and improving gut microbiota. J. Ethnopharmacol. 318 (Pt B), 116945. doi:10.1016/j.jep.2023.116945
Ding, L., Duan, Y., Yao, L., and Gao, Z. (2024). Efficacy and safety of terlipressin infusion during liver surgery: a protocol for systematic review and meta-analysis. BMJ Open 14 (3), e080562. doi:10.1136/bmjopen-2023-080562
Dong, B. S., Liu, F. Q., Yang, W. N., Li, X. D., Shi, M. J., Li, M. R., et al. (2023). Huangqi Decoction, a compound Chinese herbal medicine, inhibits the proliferation and activation of hepatic stellate cells by regulating the long noncoding RNA-C18orf26-1/microRNA-663a/transforming growth factor-β axis. J. Integr. Med. 21 (1), 47–61. doi:10.1016/j.joim.2022.11.002
Elsebaey, M. A., Tawfik, M. A., Ezzat, S., Selim, A., Elashry, H., and Abd-Elsalam, S. (2019). Endoscopic injection sclerotherapy versus N-Butyl-2 Cyanoacrylate injection in the management of actively bleeding esophageal varices: a randomized controlled trial. BMC Gastroenterol. 19 (1), 23. doi:10.1186/s12876-019-0940-1
El-Serag, H. B. (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142 (6), 1264–1273. doi:10.1053/j.gastro.2011.12.061
Engelmann, C., Zhang, I. W., and Clària, J. (2023). Mechanisms of immunity in acutely decompensated cirrhosis and acute-on-chronic liver failure. Liver Int. doi:10.1111/liv.15644
Fallon, M. B., Krowka, M. J., Brown, R. S., Trotter, J. F., Zacks, S., Roberts, K. E., et al. (2008). Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology 135 (4), 1168–1175. doi:10.1053/j.gastro.2008.06.038
Fateen, W., and Ryder, S. D. (2017). Screening for hepatocellular carcinoma: patient selection and perspectives. J. Hepatocell. Carcinoma 4, 71–79. doi:10.2147/jhc.S105777
Fernández, J., Prado, V., Trebicka, J., Amoros, A., Gustot, T., Wiest, R., et al. (2019). Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J. Hepatol. 70 (3), 398–411. doi:10.1016/j.jhep.2018.10.027
Fu, C., Zhang, Y., Xi, W. J., Xu, K., Meng, F., Ma, T., et al. (2023). Dahuang Zhechong pill attenuates hepatic sinusoidal capillarization in liver cirrhosis and hepatocellular carcinoma rat model via the MK/integrin signaling pathway. J. Ethnopharmacol. 308, 116191. doi:10.1016/j.jep.2023.116191
Gao, J., Zuo, B., and He, Y. (2024). Liver sinusoidal endothelial cells as potential drivers of liver fibrosis (Review). Mol. Med. Rep. 29 (3), 40. doi:10.3892/mmr.2024.13164
GBD 2017 Cirrhosis Collaborators (2020). The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5 (3), 245–266. doi:10.1016/s2468-1253(19)30349-8
Ginès, P., Krag, A., Abraldes, J. G., Solà, E., Fabrellas, N., and Kamath, P. S. (2021). Liver cirrhosis. Lancet 398 (10308), 1359–1376. doi:10.1016/s0140-6736(21)01374-x
Ginés, P., Quintero, E., Arroyo, V., Terés, J., Bruguera, M., Rimola, A., et al. (1987). Compensated cirrhosis: natural history and prognostic factors. Hepatology 7 (1), 122–128. doi:10.1002/hep.1840070124
Gong, Z., Deng, C., Xiao, H., Peng, Y., Hu, G., Xiang, T., et al. (2018). Effect of Dahuang Zhechong pills on long non-coding RNA growth arrest specific 5 in rat models of hepatic fibrosis. J. Tradit. Chin. Med. 38 (2), 190–196. doi:10.1016/j.jtcm.2018.04.007
Gong, Z., Lin, J., Zheng, J., Wei, L., Liu, L., Peng, Y., et al. (2020). Dahuang Zhechong pill attenuates CCl4-induced rat liver fibrosis via the PI3K-Akt signaling pathway. J. Cell Biochem. 121 (2), 1431–1440. doi:10.1002/jcb.29378
Gracia-Sancho, J., Caparrós, E., Fernández-Iglesias, A., and Francés, R. (2021). Role of liver sinusoidal endothelial cells in liver diseases. Nat. Rev. Gastroenterol. Hepatol. 18 (6), 411–431. doi:10.1038/s41575-020-00411-3
Gu, L., Zhu, Y., Lee, M., Nguyen, A., Ryujin, N. T., Huang, J. Y., et al. (2023). Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. Proc. Natl. Acad. Sci. U. S. A. 120 (19), e2300706120. doi:10.1073/pnas.2300706120
Guglielmi, F. W., Panella, C., Buda, A., Budillon, G., Caregaro, L., Clerici, C., et al. (2005). Nutritional state and energy balance in cirrhotic patients with or without hypermetabolism. Multicentre prospective study by the Nutritional Problems in Gastroenterology' Section of the Italian Society of Gastroenterology (SIGE). Dig. Liver Dis. 37 (9), 681–688. doi:10.1016/j.dld.2005.03.010
Guo, Y. C., and Lu, L. G. (2020). Antihepatic fibrosis drugs in clinical trials. J. Clin. Transl. Hepatol. 8 (3), 304–312. doi:10.14218/jcth.2020.00023
Hanai, T., Shiraki, M., Ohnishi, S., Miyazaki, T., Ideta, T., Kochi, T., et al. (2016). Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. Hepatol. Res. 46 (8), 743–751. doi:10.1111/hepr.12616
He, X., Liang, J., Li, X., Wang, Y., Zhang, X., Chen, D., et al. (2024). Dahuang zhechong pill ameliorates hepatic fibrosis by regulating gut microbiota and metabolites. J. Ethnopharmacol. 321, 117402. doi:10.1016/j.jep.2023.117402
Henkel, A. S., and Buchman, A. L. (2006). Nutritional support in patients with chronic liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 3 (4), 202–209. doi:10.1038/ncpgasthep0443
Hernandez-Gea, V., and Friedman, S. L. (2011). Pathogenesis of liver fibrosis. Annu. Rev. Pathol. 6, 425–456. doi:10.1146/annurev-pathol-011110-130246
Heusel, A. T., Rapp, S., Stamminger, T., and Scherer, M. (2024). IE1 of human cytomegalovirus inhibits necroptotic cell death via direct and indirect modulation of the necrosome complex. Viruses 16 (2), 290. doi:10.3390/v16020290
Hsu, Y. C., Yang, Y. Y., and Tsai, I. T. (2021). Lymphocyte-to-monocyte ratio predicts mortality in cirrhotic patients with septic shock. Am. J. Emerg. Med. 40, 70–76. doi:10.1016/j.ajem.2020.11.071
Hsueh, T. P., and Tsai, T. H. (2023). Exploration of sodium homeostasis and pharmacokinetics in bile duct-ligated rats treated by anti-cirrhosis herbal formula plus spironolactone. Front. Pharmacol. 14, 1092657. doi:10.3389/fphar.2023.1092657
Hu, X. Q., Song, Y. N., Wu, R., Cai, F. F., Zhang, Y., Peng, J. H., et al. (2019). Metabolic mechanisms of Fuzheng-Huayu formula against liver fibrosis in rats. J. Ethnopharmacol. 238, 111888. doi:10.1016/j.jep.2019.111888
Huang, D. Q., Terrault, N. A., Tacke, F., Gluud, L. L., Arrese, M., Bugianesi, E., et al. (2023). Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat. Rev. Gastroenterol. Hepatol. 20 (6), 388–398. doi:10.1038/s41575-023-00759-2
Huang, J., Huang, H., Jiao, Y., Ai, G., Huang, T., Li, L., et al. (2009). Effect of anluohuaxian tablet combined with gamma-IFN on schistosomal liver fibrosis. J. Huazhong Univ. Sci. Technol. Med. Sci. 29 (1), 53–58. doi:10.1007/s11596-009-0111-7
Huang, Y., Lu, J., Xu, Y., Xiong, C., Tong, D., Hu, N., et al. (2020). Xiaochaihu decorction relieves liver fibrosis caused by Schistosoma japonicum infection via the HSP47/TGF-β pathway. Parasit. Vectors 13 (1), 254. doi:10.1186/s13071-020-04121-2
Huynh, D. K., Selvanderan, S. P., Harley, H. A., Holloway, R. H., and Nguyen, N. Q. (2015). Nutritional care in hospitalized patients with chronic liver disease. World J. Gastroenterol. 21 (45), 12835–12842. doi:10.3748/wjg.v21.i45.12835
Iwasa, M., Iwata, K., Hara, N., Hattori, A., Ishidome, M., Sekoguchi-Fujikawa, N., et al. (2013). Nutrition therapy using a multidisciplinary team improves survival rates in patients with liver cirrhosis. Nutrition 29 (11-12), 1418–1421. doi:10.1016/j.nut.2013.05.016
Iwasa, M., and Takei, Y. (2015). Pathophysiology and management of hepatic encephalopathy 2014 update: ammonia toxicity and hyponatremia. Hepatol. Res. 45 (12), 1155–1162. doi:10.1111/hepr.12495
Jagst, M., Gömer, A., Todt, D., and Steinmann, E. (2024). Performance of sofosbuvir and NITD008 in extrahepatic neuronal cells against HEV. Antivir. Res. 227, 105922. doi:10.1016/j.antiviral.2024.105922
Ji, D., Chen, Y., Bi, J., Shang, Q., Liu, H., Wang, J. B., et al. (2022). Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B. J. Hepatol. 77 (6), 1515–1524. doi:10.1016/j.jhep.2022.07.018
Jiang, S. L., Hu, X. D., and Liu, P. (2015). Immunomodulation and liver protection of Yinchenhao decoction against concanavalin A-induced chronic liver injury in mice. J. Integr. Med. 13 (4), 262–268. doi:10.1016/s2095-4964(15)60185-6
Keller, C. W., Fokken, C., Turville, S. G., Lünemann, A., Schmidt, J., Münz, C., et al. (2011). TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells. J. Biol. Chem. 286 (5), 3970–3980. doi:10.1074/jbc.M110.159392
Kennedy, T. C., and Knudson, R. J. (1977). Exercise-aggravated hypoxemia and orthodeoxia in cirrhosis. Chest 72 (3), 305–309. doi:10.1378/chest.72.3.305
Kim, G., Kang, S. H., Kim, M. Y., and Baik, S. K. (2017). Prognostic value of sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis. PLoS One 12 (10), e0186990. doi:10.1371/journal.pone.0186990
Kisseleva, T., and Brenner, D. (2021). Molecular and cellular mechanisms of liver fibrosis and its regression. Nat. Rev. Gastroenterol. Hepatol. 18 (3), 151–166. doi:10.1038/s41575-020-00372-7
Kouroumalis, E., Voumvouraki, A., Augoustaki, A., and Samonakis, D. N. (2021). Autophagy in liver diseases. World J. Hepatol. 13 (1), 6–65. doi:10.4254/wjh.v13.i1.6
Krenkel, O., Puengel, T., Govaere, O., Abdallah, A. T., Mossanen, J. C., Kohlhepp, M., et al. (2018). Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology 67 (4), 1270–1283. doi:10.1002/hep.29544
Lebossé, F., Gudd, C., Tunc, E., Singanayagam, A., Nathwani, R., Triantafyllou, E., et al. (2019). CD8(+)T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction. EBioMedicine 49, 258–268. doi:10.1016/j.ebiom.2019.10.011
Lenz, K., Binder, M., Buder, R., Gruber, A., Gutschreiter, B., and Voglmayr, M. (2014). Renal insufficiency in patients with hepatic insufficiency. Med. Klin. Intensivmed. Notfmed 109 (4), 240–245. doi:10.1007/s00063-013-0322-3
Li, H. (2020). Advances in anti hepatic fibrotic therapy with Traditional Chinese Medicine herbal formula. J. Ethnopharmacol. 251, 112442. doi:10.1016/j.jep.2019.112442
Li, H. (2022). Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma. Dig. Liver Dis. 54 (5), 598–613. doi:10.1016/j.dld.2021.07.006
Li, W. K., Wang, G. F., Wang, T. M., Li, Y. Y., Li, Y. F., Lu, X. Y., et al. (2019). Protective effect of herbal medicine Huangqi decoction against chronic cholestatic liver injury by inhibiting bile acid-stimulated inflammation in DDC-induced mice. Phytomedicine 62, 152948. doi:10.1016/j.phymed.2019.152948
Liu, C., Cai, J., Cheng, Z., Dai, X., Tao, L., Zhang, J., et al. (2015). Xiayuxue decoction reduces renal injury by promoting macrophage apoptosis in hepatic cirrhotic rats. Genet. Mol. Res. 14 (3), 10760–10773. doi:10.4238/2015.September.9.15
Liu, C., Sun, M., Wang, L., Wang, G., Chen, G., Liu, C., et al. (2008). Effects of Yinchenhao Tang and related decoctions on DMN-induced cirrhosis/fibrosis in rats. Chin. Med. 3, 1. doi:10.1186/1749-8546-3-1
Liu, C., Wang, G., Chen, G., Mu, Y., Zhang, L., Hu, X., et al. (2012). Huangqi decoction inhibits apoptosis and fibrosis, but promotes Kupffer cell activation in dimethylnitrosamine-induced rat liver fibrosis. BMC Complement. Altern. Med. 12, 51. doi:10.1186/1472-6882-12-51
Liu, F., Tian, S., Liu, Q., Deng, Y., He, Q., Shi, Q., et al. (2024). Comparison of genomic alterations in Epstein-Barr virus-positive and Epstein-Barr virus-negative diffuse large B-cell lymphoma. Cancer Med. 13 (4), e6995. doi:10.1002/cam4.6995
Liu, H. L., Lv, J., Zhao, Z. M., Xiong, A. M., Tan, Y., Glenn, J. S., et al. (2019). Fuzhenghuayu Decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis. Sci. Rep. 9 (1), 18719. doi:10.1038/s41598-019-54663-4
Liu, L., Zhou, Y., Dai, D., Xia, H., Zhao, K., and Zhang, J. (2018). Protective effects of Kangxian ruangan capsule against nonalcoholic fatty liver disease fibrosis in rats induced by MCD diet. Biomed. Pharmacother. 108, 424–434. doi:10.1016/j.biopha.2018.06.134
Liu, P., Hu, Y. Y., Liu, C., Xu, L. M., Liu, C. H., Sun, K. W., et al. (2005). Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B. World J. Gastroenterol. 11 (19), 2892–2899. doi:10.3748/wjg.v11.i19.2892
Liu, Y. Q., Zhang, C., Li, J. W., Cao, L. H., Zhang, Z. Q., Zhao, W. F., et al. (2023). An-Luo-Hua-Xian pill improves the regression of liver fibrosis in chronic hepatitis B patients treated with entecavir. J. Clin. Transl. Hepatol. 11 (2), 304–313. doi:10.14218/jcth.2022.00091
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., et al. (2016). Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 2, 16018. doi:10.1038/nrdp.2016.18
Luo, L., Yao, X., and Yang, W. (2023). Biejia-Ruangan compound and incidence of hepatocellular carcinoma. J. Hepatol. 78 (4), e141–e142. doi:10.1016/j.jhep.2022.11.012
Ma, W., Tao, L., Zhang, W., Zhu, Y., Xue, D., Zhang, J., et al. (2017). Xia-yu-xue decoction inhibits intestinal epithelial cell apoptosis in CCl4-induced liver fibrosis. Cell Physiol. Biochem. 44 (1), 333–344. doi:10.1159/000484904
Machicao, V. I., Balakrishnan, M., and Fallon, M. B. (2014). Pulmonary complications in chronic liver disease. Hepatology 59 (4), 1627–1637. doi:10.1002/hep.26745
Malick, M., Shahid, W., Lateef, A., Zubair, Z., and Zaidi, S. M. (2023). Hepatic hydrothorax without ascites: a diagnostic and management challenge. J. Ayub Med. Coll. Abbottabad 35 (4), S801–S803. doi:10.55519/jamc-s4-12094
Mancak, M., Altintas, D., Balaban, Y., and Caliskan, U. K. (2024). Evidence-based herbal treatments in liver diseases. Hepatol. Forum 5 (1), 50–60. doi:10.14744/hf.2022.2022.0052
Manolakopoulos, S., Triantos, C., Theodoropoulos, J., Vlachogiannakos, J., Kougioumtzan, A., Papatheodoridis, G., et al. (2009). Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J. Hepatol. 51 (3), 468–474. doi:10.1016/j.jhep.2009.05.031
Maqsood, S., Saleem, A., Iqbal, A., and Butt, J. A. (2006). Precipitating factors of hepatic encephalopathy: experience at Pakistan institute of medical Sciences islamabad. J. Ayub Med. Coll. Abbottabad 18 (4), 58–62.
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., et al. (2013). Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381 (9865), 468–475. doi:10.1016/s0140-6736(12)61425-1
Marjot, T., Ray, D. W., Williams, F. R., Tomlinson, J. W., and Armstrong, M. J. (2021). Sleep and liver disease: a bidirectional relationship. Lancet Gastroenterol. Hepatol. 6 (10), 850–863. doi:10.1016/s2468-1253(21)00169-2
McConnell, M. J., Kostallari, E., Ibrahim, S. H., and Iwakiri, Y. (2023). The evolving role of liver sinusoidal endothelial cells in liver health and disease. Hepatology 78 (2), 649–669. doi:10.1097/hep.0000000000000207
Meng, X., Pan, Z., Zhao, J., and Feng, Q. (2022). Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for chronic hepatitis B liver fibrosis: a systematic review and meta-analysis. Med. Baltim. 101 (46), e31664. doi:10.1097/md.0000000000031664
Meola, M., Nalesso, F., Petrucci, I., Samoni, S., and Ronco, C. (2016). Clinical scenarios in acute kidney injury: hepatorenal syndrome. Contrib. Nephrol. 188, 33–38. doi:10.1159/000445465
Møller, S., Krag, A., Madsen, J. L., Henriksen, J. H., and Bendtsen, F. (2009). Pulmonary dysfunction and hepatopulmonary syndrome in cirrhosis and portal hypertension. Liver Int. 29 (10), 1528–1537. doi:10.1111/j.1478-3231.2009.02103.x
Morgan, T. R., Ghany, M. G., Kim, H. Y., Snow, K. K., Shiffman, M. L., De Santo, J. L., et al. (2010). Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 52 (3), 833–844. doi:10.1002/hep.23744
Ney, M., Gramlich, L., Mathiesen, V., Bailey, R. J., Haykowsky, M., Ma, M., et al. (2017). Patient-perceived barriers to lifestyle interventions in cirrhosis. Saudi J. Gastroenterol. 23 (2), 97–104. doi:10.4103/1319-3767.203357
Ni, Y., Li, J. M., Liu, M. K., Zhang, T. T., Wang, D. P., Zhou, W. H., et al. (2017). Pathological process of liver sinusoidal endothelial cells in liver diseases. World J. Gastroenterol. 23 (43), 7666–7677. doi:10.3748/wjg.v23.i43.7666
Nie, G., Zhang, H., Xie, D., Yan, J., and Li, X. (2023). Liver cirrhosis and complications from the perspective of dysbiosis. Front. Med. (Lausanne) 10, 1320015. doi:10.3389/fmed.2023.1320015
Park, J., Kim, J., Lewy, T., Rice, C. M., Elemento, O., Rendeiro, A. F., et al. (2022). Spatial omics technologies at multimodal and single cell/subcellular level. Genome Biol. 23 (1), 256. doi:10.1186/s13059-022-02824-6
Periyalwar, P., and Dasarathy, S. (2012). Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clin. Liver Dis. 16 (1), 95–131. doi:10.1016/j.cld.2011.12.009
Piano, S., Tonon, M., and Angeli, P. (2021). Changes in the epidemiology and management of bacterial infections in cirrhosis. Clin. Mol. Hepatol. 27 (3), 437–445. doi:10.3350/cmh.2020.0329
Plauth, M., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., et al. (2019). ESPEN guideline on clinical nutrition in liver disease. Clin. Nutr. 38 (2), 485–521. doi:10.1016/j.clnu.2018.12.022
Ponziani, F. R., and Gasbarrini, A. (2018). Sarcopenia in patients with advanced liver disease. Curr. Protein Pept. Sci. 19 (7), 681–691. doi:10.2174/1389203718666170428121647
Pratama, V., Budiono, J., Thobari, J. A., Widyantoro, B., Anggraeni, V. Y., and Dinarti, L. K. (2024). The role of tolvaptan add-on therapy in patients with acute heart failure: a systematic review and network meta-analysis. Front. Cardiovasc Med. 11, 1367442. doi:10.3389/fcvm.2024.1367442
Pun, C. K., Huang, H. C., Chang, C. C., Hsu, S. J., Huang, Y. H., Hou, M. C., et al. (2024). Hepatic encephalopathy: from novel pathogenesis mechanism to emerging treatments. J. Chin. Med. Assoc. 87 (3), 245–251. doi:10.1097/jcma.0000000000001041
Qi, L., Li, S., Xu, J., Xu, J., Lou, W., Cheng, L., et al. (2020). Acupuncture for the treatment of liver cirrhosis: a meta-analysis. Gastroenterol. Res. Pract. 2020, 4054781. doi:10.1155/2020/4054781
Qiang, R., Zhang, Y., and Wang, Y. (2022). Mechanisms of xiaochaihu decoction on treating hepatic fibrosis explored by network pharmacology. Dis. Markers 2022, 8925637. doi:10.1155/2022/8925637
Qiu, J., Thapaliya, S., Runkana, A., Yang, Y., Tsien, C., Mohan, M. L., et al. (2013). Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism. Proc. Natl. Acad. Sci. U. S. A. 110 (45), 18162–18167. doi:10.1073/pnas.1317049110
Rad, N. K., Heydari, Z., Tamimi, A. H., Zahmatkesh, E., Shpichka, A., Barekat, M., et al. (2024). Review on kidney-liver crosstalk: pathophysiology of their disorders. Cell J. 26 (2), 98–111. doi:10.22074/cellj.2023.2007757.1376
Rajpurohit, S., Musunuri, B., Shailesh, B., Mohan, P., and Shetty, S. (2022). Novel drugs for the management of hepatic encephalopathy: still a long journey to travel. J. Clin. Exp. Hepatol. 12 (4), 1200–1214. doi:10.1016/j.jceh.2022.01.012
Rajput, M., Choudhary, K., Kumar, M., Vivekanand, V., Chawade, A., Ortiz, R., et al. (2021). RNA interference and CRISPR/cas gene editing for crop improvement: paradigm shift towards sustainable agriculture. Plants (Basel) 10 (9), 1914. doi:10.3390/plants10091914
Ren, C., Liu, Q., Wei, Q., Cai, W., He, M., Du, Y., et al. (2017). Circulating miRNAs as potential biomarkers of age-related macular degeneration. Cell Physiol. Biochem. 41 (4), 1413–1423. doi:10.1159/000467941
Rodríguez-Roisin, R., and Krowka, M. J. (2008). Hepatopulmonary syndrome--a liver-induced lung vascular disorder. N. Engl. J. Med. 358 (22), 2378–2387. doi:10.1056/NEJMra0707185
Roehlen, N., Crouchet, E., and Baumert, T. F. (2020). Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells 9 (4), 875. doi:10.3390/cells9040875
Romanelli, R. G., and Stasi, C. (2016). Recent advancements in diagnosis and therapy of liver cirrhosis. Curr. Drug Targets 17 (15), 1804–1817. doi:10.2174/1389450117666160613101413
Rong, G., Chen, Y., Yu, Z., Li, Q., Bi, J., Tan, L., et al. (2022). Synergistic effect of biejia-ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: a multicenter, randomized, double-blind, placebo-controlled trial. J. Infect. Dis. 225 (6), 1091–1099. doi:10.1093/infdis/jiaa266
Runyon, B. A., Montano, A. A., Akriviadis, E. A., Antillon, M. R., Irving, M. A., and McHutchison, J. G. (1992). The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann. Intern Med. 117 (3), 215–220. doi:10.7326/0003-4819-117-3-215
Schuppan, D., and Afdhal, N. H. (2008). Liver cirrhosis. Lancet 371 (9615), 838–851. doi:10.1016/s0140-6736(08)60383-9
Shen, T. C., Albenberg, L., Bittinger, K., Chehoud, C., Chen, Y. Y., Judge, C. A., et al. (2015). Engineering the gut microbiota to treat hyperammonemia. J. Clin. Invest. 125 (7), 2841–2850. doi:10.1172/jci79214
Shi, K., Wen, J., Zeng, J., Guo, Y., Hu, J., Li, C., et al. (2021). Preclinical evidence of Yinchenhao decoction on cholestasis: a systematic review and meta-analysis of animal studies. Phytother. Res. 35 (1), 138–154. doi:10.1002/ptr.6806
Simonetto, D. A., Gines, P., and Kamath, P. S. (2020). Hepatorenal syndrome: pathophysiology, diagnosis, and management. Bmj 370, m2687. doi:10.1136/bmj.m2687
Sinclair, M., Gow, P. J., Grossmann, M., and Angus, P. W. (2016). Review article: sarcopenia in cirrhosis--aetiology, implications and potential therapeutic interventions. Aliment. Pharmacol. Ther. 43 (7), 765–777. doi:10.1111/apt.13549
Sobhonslidsuk, A. (2015). Current position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome. World J. Gastrointest. Pharmacol. Ther. 6 (3), 28–31. doi:10.4292/wjgpt.v6.i3.28
Solé, C., Guilly, S., Da Silva, K., Llopis, M., Le-Chatelier, E., Huelin, P., et al. (2021). Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: relationship with acute-on-chronic liver failure and prognosis. Gastroenterology 160 (1), 206–218.e13. doi:10.1053/j.gastro.2020.08.054
Song, J. E., and Kim, B. S. (2019). Endoscopic therapy and radiologic intervention of acute gastroesophageal variceal bleeding. Clin. Endosc. 52 (5), 407–415. doi:10.5946/ce.2019.178
Song, Y., Zhao, J., Wang, S., Huang, H., Hong, J., Zuo, J., et al. (2019). The efficacy of Chinese patent medicine combined with entecavir for the treatment of chronic HBV-related liver fibrosis or cirrhosis: protocol for a systematic review and meta-analysis of randomized controlled trials or prospective cohort studies. Med. Baltim. 98 (22), e15732. doi:10.1097/md.0000000000015732
Song, Y. N., Chen, J., Cai, F. F., Lu, Y. Y., Chen, Q. L., Zhang, Y. Y., et al. (2018). A metabolic mechanism analysis of Fuzheng-Huayu formula for improving liver cirrhosis with traditional Chinese medicine syndromes. Acta Pharmacol. Sin. 39 (6), 942–951. doi:10.1038/aps.2017.101
Sousa, M., Fernandes, S., Proença, L., Silva, A. P., Leite, S., Silva, J., et al. (2017). The Baveno VI criteria for predicting esophageal varices: validation in real life practice. Rev. Esp. Enferm. Dig. 109 (10), 704–707. doi:10.17235/reed.2017.5052/2017
Starr, S. P., and Raines, D. (2011). Cirrhosis: diagnosis, management, and prevention. Am. Fam. Physician 84 (12), 1353–1359.
Sun, C., Gao, M., and Qiao, M. (2023). Research progress of traditional Chinese medicine compound "Xiaochaihu Decoction" in the treatment of depression. Biomed. Pharmacother. 159, 114249. doi:10.1016/j.biopha.2023.114249
Sun, Z., Guo, Y., Xu, X., Zhou, C., Luo, X., Shen, Z., et al. (2024). Hydronidone induces apoptosis in activated hepatic stellate cells through endoplasmic reticulum stress-associated mitochondrial apoptotic pathway. J. Gastroenterol. Hepatol. doi:10.1111/jgh.16635
Tandon, P., and Garcia-Tsao, G. (2008). Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin. Liver Dis. 28 (1), 26–42. doi:10.1055/s-2008-1040319
Tandon, P., Montano-Loza, A. J., Lai, J. C., Dasarathy, S., and Merli, M. (2021). Sarcopenia and frailty in decompensated cirrhosis. J. Hepatol. 75 (Suppl. 1), S147–s162. doi:10.1016/j.jhep.2021.01.025
Tapper, E. B., and Parikh, N. D. (2023). Diagnosis and management of cirrhosis and its complications: a review. Jama 329 (18), 1589–1602. doi:10.1001/jama.2023.5997
Tian, M., Liu, W., You, H., Zhao, Q., Ouyang, L., Gao, B., et al. (2016). Protective effect of Yiguanjian decoction against DNA damage on concanavalin A-induced liver injury mice model. J. Tradit. Chin. Med. 36 (4), 471–478. doi:10.1016/s0254-6272(16)30064-4
Toh, M. R., Wong, E. Y. T., Wong, S. H., Ng, A. W. T., Loo, L. H., Chow, P. K., et al. (2023). Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology 164 (5), 766–782. doi:10.1053/j.gastro.2023.01.033
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., et al. (2018). The gut-liver axis and the intersection with the microbiome. Nat. Rev. Gastroenterol. Hepatol. 15 (7), 397–411. doi:10.1038/s41575-018-0011-z
Varghese, J., Ilias-basha, H., Dhanasekaran, R., Singh, S., and Venkataraman, J. (2007). Hepatopulmonary syndrome - past to present. Ann. Hepatol. 6 (3), 135–142. doi:10.1016/s1665-2681(19)31918-0
Wang, M., Liu, W., Ge, J., and Liu, S. (2023b). The immunomodulatory mechanisms for acupuncture practice. Front. Immunol. 14, 1147718. doi:10.3389/fimmu.2023.1147718
Wang, S. J., Ye, W., Li, W. Y., Tian, W., Zhang, M., Sun, Y., et al. (2023a). Effects and mechanisms of Xiaochaihu Tang against liver fibrosis: an integration of network pharmacology, molecular docking and experimental validation. J. Ethnopharmacol. 303, 116053. doi:10.1016/j.jep.2022.116053
Wang, X. L., Jia, D. W., Liu, H. Y., Yan, X. F., Ye, T. J., Hu, X. D., et al. (2012). Effect of Yiguanjian decoction on cell differentiation and proliferation in CCl₄-treated mice. World J. Gastroenterol. 18 (25), 3235–3249. doi:10.3748/wjg.v18.i25.3235
Wang, Y., Li, Y., Zhang, H., Zhu, L., Zhong, J., Zeng, J., et al. (2021). Pharmacokinetics-based comprehensive strategy to identify multiple effective components in Huangqi decoction against liver fibrosis. Phytomedicine 84, 153513. doi:10.1016/j.phymed.2021.153513
Wazir, H., Abid, M., Essani, B., Saeed, H., Ahmad Khan, M., Nasrullah, F., et al. (2023). Diagnosis and treatment of liver disease: current trends and future directions. Cureus 15 (12), e49920. doi:10.7759/cureus.49920
Wei, F., Lang, Y., Gong, D., and Fan, Y. (2015). Effect of Dahuang zhechong formula on liver fibrosis in patients with chronic hepatitis B: a meta-analysis. Complement. Ther. Med. 23 (1), 129–138. doi:10.1016/j.ctim.2014.12.011
Weinfurtner, K., and Forde, K. (2020). Hepatopulmonary syndrome and portopulmonary hypertension: current status and implications for liver transplantation. Curr. Hepatol. Rep. 19 (3), 174–185. doi:10.1007/s11901-020-00532-y
Welch, N., Dasarathy, J., Runkana, A., Penumatsa, R., Bellar, A., Reen, J., et al. (2020). Continued muscle loss increases mortality in cirrhosis: impact of aetiology of liver disease. Liver Int. 40 (5), 1178–1188. doi:10.1111/liv.14358
Wu, H. H. L., Rakisheva, A., Ponnusamy, A., and Chinnadurai, R. (2024). Hepatocardiorenal syndrome in liver cirrhosis: recognition of a new entity? World J. Gastroenterol. 30 (2), 128–136. doi:10.3748/wjg.v30.i2.128
Xiao, H. M., Shi, M. J., Jiang, J. M., Cai, G. S., Xie, Y. B., Tian, G. J., et al. (2022). Efficacy and safety of AnluoHuaxian pills on chronic hepatitis B with normal or minimally elevated alanine transaminase and early liver fibrosis: a randomized controlled trial. J. Ethnopharmacol. 293, 115210. doi:10.1016/j.jep.2022.115210
Xu, Y., Fan, W. W., Xu, W., Jiang, S. L., Chen, G. F., Liu, C., et al. (2018). Yiguanjian decoction enhances fetal liver stem/progenitor cell-mediated repair of liver cirrhosis through regulation of macrophage activation state. World J. Gastroenterol. 24 (42), 4759–4772. doi:10.3748/wjg.v24.i42.4759
Xu, Y., Xu, W., Liu, W., Chen, G., Jiang, S., Chen, J., et al. (2021). Yiguanjian decoction inhibits macrophage M1 polarization and attenuates hepatic fibrosis induced by CCl(4)/2-AAF. Pharm. Biol. 59 (1), 1150–1160. doi:10.1080/13880209.2021.1961820
Yang, F. R., Fang, B. W., and Lou, J. S. (2013). Effects of fufang Biejia ruangan pills on hepatic fibrosis in vivo and in vitro. World J. Gastroenterol. 19 (32), 5326–5333. doi:10.3748/wjg.v19.i32.5326
Yang, J., Chen, Y., Jing, Y., Green, M. R., and Han, L. (2023). Advancing CAR T cell therapy through the use of multidimensional omics data. Nat. Rev. Clin. Oncol. 20 (4), 211–228. doi:10.1038/s41571-023-00729-2
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., and Roberts, L. R. (2019). A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 16 (10), 589–604. doi:10.1038/s41575-019-0186-y
Yao, C. K., Fung, J., Chu, N. H. S., and Tan, V. P. Y. (2018). Dietary interventions in liver cirrhosis. J. Clin. Gastroenterol. 52 (8), 663–673. doi:10.1097/mcg.0000000000001071
Ye, Z., Huang, Q., She, Y., Hu, Y., Wu, M., Qin, K., et al. (2022). A meritorious integrated medical regimen for hepatic fibrosis and its complications via the systematic review and meta-analysis for Dahuang Zhechong pill-based therapy. Front. Med. (Lausanne) 9, 920062. doi:10.3389/fmed.2022.920062
You, X., Jiang, F., and Zhang, Y. (2023). Clinical effects of combined treatment of traditional Chinese medicine and western medicine for viral hepatitis B cirrhosis and the effects on serum miR-122, miR-200a. Biotechnol. Genet. Eng. Rev., 1–15. doi:10.1080/02648725.2023.2202531
Zhang, D., Zhang, L., Chen, G., Xu, Y., Yang, H., Xiao, Z., et al. (2020). Hepatoprotective effect of Xiayuxue decoction ethyl acetate fraction against carbon tetrachloride-induced liver fibrosis in mice via inducing apoptosis and suppressing activation of hepatic stellate cells. Pharm. Biol. 58 (1), 1229–1243. doi:10.1080/13880209.2020.1855212
Zhang, D., Zhao, G., Li, L., and Li, Z. (2017). Observation of combined/optimized therapy of Lamivudine and Adefovir Dipivoxyl for hepatitis B-induced decompensated cirrhosis with baseline HBV DNA>1,000 IU/mL. Acta Gastroenterol. Belg 80 (1), 9–13.
Zhang, F., Ma, J., Lu, Y., Ni, G. X., Ni, C. Y., Zhang, X. J., et al. (2012a). Acupuncture combined with curcumin attenuates carbon tetrachloride-induced hepatic fibrosis in rats. Acupunct. Med. 30 (2), 132–138. doi:10.1136/acupmed-2011-010116
Zhang, G. B., Song, Y. N., Chen, Q. L., Dong, S., Lu, Y. Y., Su, M. Y., et al. (2015). Actions of Huangqi decoction against rat liver fibrosis: a gene expression profiling analysis. Chin. Med. 10, 39. doi:10.1186/s13020-015-0066-5
Zhang, X. P., Zhang, F., Zhang, Z. L., Ma, J., Kong, D. S., Ni, G. X., et al. (2012b). Acupuncture combined with curcumin disrupts platelet-derived growth factor β receptor/extracellular signal-regulated kinase signalling and stimulates extracellular matrix degradation in carbon tetrachloride-induced hepatic fibrosis in rats. Acupunct. Med. 30 (4), 324–330. doi:10.1136/acupmed-2012-010167
Zhou, J., Liang, Y., Lin, X. M., Ma, R. J., and Fang, J. Q. (2012). Acupuncture in treating hepatic fibrosis: a review with recommendation for future studies. Afr. J. Tradit. Complement. Altern. Med. 9 (4), 452–458. doi:10.4314/ajtcam.v9i4.1
Keywords: liver cirrhosis, current status, treatment options, Chinese medicine, pharmacology
Citation: Zheng S, Xue C, Li S, Zao X, Li X, Liu Q, Cao X, Wang W, Qi W, Du H, Zhang P and Ye Y (2024) Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine. Front. Pharmacol. 15:1381476. doi: 10.3389/fphar.2024.1381476
Received: 03 February 2024; Accepted: 28 June 2024;
Published: 16 July 2024.
Edited by:
Norsham Juliana, Universiti Sains Islam Malaysia, MalaysiaReviewed by:
Yin-Hu Wang, New York University, United StatesQuansheng Feng, Chengdu University of Traditional Chinese Medicine, China
Mingyu Sun, Shanghai University of Traditional Chinese Medicine, China
Liang Shan, Anhui Medical University, China
Copyright © 2024 Zheng, Xue, Li, Zao, Li, Liu, Cao, Wang, Qi, Du, Zhang and Ye. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Peng Zhang, zp891223@126.com; Yongan Ye, yeyongan@vip.163.com